German biotech firm BioNTech said on Tuesday it had secured almost $450 million in government funding to speed up work on its COVID-19 vaccine candidate and expand its production capacity in Germany. BioNTech and partners Pfizer Inc and China’s Shanghai Fosun Pharmaceutical Group Co Ltd are among the leading developers of experimental COVID-19 vaccines, based on molecules carrying a genetic code called messenger RNA (mRNA). Mainz-based BioNTech, founded in 2008 and listed on the Nasdaq exchange last year, said it had been awarded 375 million euros ($445 million) in funding, after applying under a scheme announced in July …read more
Source:: Yahoo Finance
